Chimeric antigen receptor-based therapies beyond cancer.

Autor: Velasco-de Andrés M; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain., Muñoz-Sánchez G; Servei d'Immunologia, Centre de Diagnòstic Biomèdic, Hospital Clínic de Barcelona, Barcelona, Spain., Carrillo-Serradell L; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain., Gutiérrez-Hernández MDM; Servei d'Hematologia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain., Català C; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain., Isamat M; Sepsia Therapeutics S.L., L'Hospitalet de Llobregat, Spain., Lozano F; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Servei d'Immunologia, Centre de Diagnòstic Biomèdic, Hospital Clínic de Barcelona, Barcelona, Spain.; Departament de Biomedicina, Facultat de Medicina, Universitat de Barcelona, Barcelona, Spain.
Jazyk: angličtina
Zdroj: European journal of immunology [Eur J Immunol] 2023 Mar; Vol. 53 (3), pp. e2250184. Date of Electronic Publication: 2023 Feb 06.
DOI: 10.1002/eji.202250184
Abstrakt: Adoptive cell transfer (ACT) therapies have gained renewed interest in the field of immunotherapy following the advent of chimeric antigen receptor (CAR) technology. This immunological breakthrough requires immune cell engineering with an artificial surface protein receptor for antigen-specific recognition coupled to an intracellular protein domain for cell activating functions. CAR-based ACT has successfully solved some hematological malignancies, and it is expected that other tumors may soon benefit from this approach. However, the potential of CAR technology is such that other immune-mediated disorders are beginning to profit from it. This review will focus on CAR-based ACT therapeutic areas other than oncology such as infection, allergy, autoimmunity, transplantation, and fibrotic repair. Herein, we discuss the results and limitations of preclinical and clinical studies in that regard.
(© 2023 The Authors. European Journal of Immunology published by Wiley-VCH GmbH.)
Databáze: MEDLINE
Externí odkaz: